GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » Net Cash per Share

InnoCan Pharma (XCNQ:INNO) Net Cash per Share : C$0.01 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). InnoCan Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 was C$0.01.

The historical rank and industry rank for InnoCan Pharma's Net Cash per Share or its related term are showing as below:

XCNQ:INNO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 10.75   Med: 18   Max: 32
Current: 28.5

During the past 6 years, the highest Price-to-Net-Cash Ratio of InnoCan Pharma was 32.00. The lowest was 10.75. And the median was 18.00.

XCNQ:INNO's Price-to-Net-Cash is ranked worse than
79.77% of 257 companies
in the Drug Manufacturers industry
Industry Median: 7.7 vs XCNQ:INNO: 28.50

InnoCan Pharma Net Cash per Share Historical Data

The historical data trend for InnoCan Pharma's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCan Pharma Net Cash per Share Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial 0.01 -0.04 0.04 0.02 0.01

InnoCan Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.01 0.01 0.01

Competitive Comparison of InnoCan Pharma's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Price-to-Net-Cash falls into.



InnoCan Pharma Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

InnoCan Pharma's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(5.212-3.426-0.38)/268.002
=0.01

InnoCan Pharma's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(5.212-3.426-0.38)/268.002
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCan Pharma  (XCNQ:INNO) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


InnoCan Pharma Net Cash per Share Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCan Pharma (XCNQ:INNO) Business Description

Traded in Other Exchanges
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma (XCNQ:INNO) Headlines

From GuruFocus

Innocap, Inc.'s Current Activities

By Marketwired Marketwired 05-24-2018

President of Innocap, Inc. is in Singapore

By GlobeNewswire GlobeNewswire 05-03-2018

Innocap, Inc. Year End Message To Shareholders

By PRNewswire PRNewswire 12-14-2020

President of Innocap, Inc. is in Singapore

By Marketwired Marketwired 05-03-2018